Europe Bovine Pericardial Valve Market to Grow at a CAGR of 9.4% to reach US$ 1,229.57 Million from 2020 to 2027

The Europe bovine pericardial valve market is expected to reach US$ 1,229.57 million by 2027 from US$ 604.77 million in 2019; it is estimated to grow at a CAGR of 9.4% from 2020 to 2027.

The key factors driving the growth of bovine pericardial valve are increasing incidence of cardiovascular diseases (CVD) and congenital heart diseases (CHD) and advantages of tissue-based heart valves over mechanical valves in the region. However, limitations associated with the tissue-based valves is the major factor hindering the bovine pericardial valve market growth in Europe.

A bovine pericardial valve is also known as a bioprosthetic valve, and it is used for applications such as bio-prosthetic heart valves, dural closure, bone and dental membranes, and surgical buttressing. A bovine pericardial valve is made from collagen and other metallic material or alloy, which provides strength and elasticity.

Congenital heart diseases (CHD) are a major cause for mortality and morbidity. These diseases are usually defined as clinically significant structural heart diseases that occur from the birth. CHD comprises the most common types of birth defects. However, with the advancement in medical science, people suffering from CHD are able to live longer and healthier. According to the NHS, Congenital heart disease is one of the most common types of birth defect, affecting up to 8 in every 1,000 babies born in the UK. According to the NICOR (National Institute for Cardiovascular Outcomes Research) data from 2014, 47% of children in the UK requiring surgery or intervention within the first year of life for CHD were diagnosed antenatally. For instance, according to a survey published in 2018, by International Open Access Journal Covering Cardiovascular Medicine and Surgery, the incidence of CHD in Germany is found approximately among 5-8 people per 1000 births.

Similarly, the cardiovascular diseases (CVD) also pose a significant threat to human health and lead to a remarkable burden on developed economies. For Instance, CVDs are the major cause of death in Europe, especially in UK. In 2003, about 233,000 deaths were estimated in UK. More than 1 in 3 people (38%) die from CVD. Access to essential care for non-communicable diseases such as CVDs through medications and surgical treatments helps to save millions of lives every year. Thus, the increasing incidence of these diseases across European region is expected to augment the demand for bovine pericardial valve market during the forecast period.

The dramatic spread of COVID-19 across various countries in Europe has disrupted lives, livelihood, communities as well as business across the Europe. Organizations, including the Forum and its partners, are coming together and innovating to minimize the impact on public health and to limit disruptions to economies and supply chains. For instance, the European Cardiology Society (ESC) conducted The European Association Percutaneous Cardiovascular Interventions (ECPAI) to study and focus on the impact of COVID-19 on various patients suffering with cardiovascular diseases as well as plans to combat the loss of the business due to the virus.

Rest of Europe Bovine pericardial valve Market, Revenue and Forecast to 2027 (US$ Mn)

EUROPE BOVINE PERICARDIAL VALVE MARKET SEGMENTATION

By Valve Type

• Aortic
• Mitral
• Others

By Alloy

• Cobalt-chrome
• Titanium
• Nickel Molybdenum
• Others

By End-User

• Hospitals
• Cardiac Centers
• Ambulatory Surgical Centers

By Country

• Germany
• France
• United Kingdom
• Italy
• Spain

Company Profiles

• AFFLUENT MEDICAL SA
• Boston Scientific Corporation
• Edwards Lifesciences Corporation
• Medtronic
• LivaNova PLC

Europe Bovine Pericardial Valve Report Scope